ArticleClinical journal of the American Society of Nephrology : CJASN2021
Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05057936 (Antibody Response After COVID-19 Vaccination in Chronic Kidney Disease and Kidney Transplant Patients), which is not on this map. Cited by 207 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antibody Response After COVID-19 Vaccination in Chronic Kidney Disease and Kidney Transplant Patients
Who cites it
207 citing papers in PubMed, 6 syntheses or guidelines pooled it, 345 citations in OpenAlex.
- Pooled it
- COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies.Frontiers in pharmacology · 2023Pooled it
- Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Pooled it
- Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- Identification of Clinical Factors Associated With the Immunogenicity of Homologous ChAdOx1-nCoV-19 Vaccine in Hemodialysis Patients.The Kaohsiung journal of medical sciences · 2026Article
- Expression levels of SARS-CoV-2 IgM, IgG, and neutralizing antibodies in a Chinese cohort and detection of peptide-specific antibodies in COVID-19 patients.BMC infectious diseases · 2026Article
- The Role of the Gut Microbiota and Uraemic Toxins in Vaccine Responsiveness Among People Receiving Maintenance Haemodialysis.Vaccines · 2026Article
- Mortality comparison between the COVID-19 Omicron variant and influenza among patients with end-stage kidney disease: a nationwide population-based retrospective cohort study.Clinical and experimental nephrology · 2026Article
- Chronic heart failure and hypoalbuminemia are risk factors of poorer mRNA SARS-CoV-2 vaccine response in maintenance Hemodialysis patients (the COVaccinDia study).BMC nephrology · 2025Observational
- Article
- Composition of peripheral blood immune cell compartment in stage 5 chronic kidney disease is affected by smoking and other risk factors associated with systemic inflammatory response.Frontiers in immunology · 2025Article
- Status of COVID-19 vaccination in patients undergoing dialysis in China: a national cross-sectional study (2022).Frontiers in public health · 2025Article
- Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.New microbes and new infections · 2024Article
- Tixagevimab-cilgavimab for preventing breakthrough COVID-19 in dialysis patients: a prospective study.Clinical kidney journal · 2024Article
- Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study.BMC nephrology · 2024Observational
- Article
- Network Analysis of Dysregulated Immune Response to COVID-19 mRNA Vaccination in Hemodialysis Patients.Vaccines · 2024Article
- Hesitation towards COVID-19 booster vaccination among dialysis patients: a cross-sectional study in Taizhou, China.BMC infectious diseases · 2024Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesCoronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients on maintenance hemodialysis and the factors associated with it. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included 56 patients on maintenance hemodialysis (dialysis group) and a control group composed of 95 health care workers. All participants had received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine. The serology testing was done using Quant II IgG anti-Spike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay by Abbott a median of 30 days after receipt of the second dose of the vaccine.
resultsAll subjects in the control group developed an antibody response compared with 96% (54 of 56) positive responders in the dialysis group. The IgG levels in the dialysis group (median, 2900; interquartile range, 1128-5651) were significantly lower than in the control group (median, 7401; interquartile range, 3687-15,471). A Mann-Whitney
conclusionsAlthough most patients on maintenance hemodialysis developed a substantial humoral response following the BNT162b2 vaccine, it was significantly lower than controls. Age was an important factor in the humoral response, regardless of chronic medical conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.